KÜPELİ, S. Et Al. 2022. Total nucleated cell dose in graft is a better prognostic factor for survival in pediatric patients transplanted with bone marrow compared to CD34+, CD3+, or total mononuclear cell count. JOURNAL OF CLINICAL APHERESIS , vol.37, no.1 , 19-24.

KÜPELİ, S., Inan, G., Ozkan, A., Sezgin, G., Bayram, I., & Tanyeli, A., (2022). Total nucleated cell dose in graft is a better prognostic factor for survival in pediatric patients transplanted with bone marrow compared to CD34+, CD3+, or total mononuclear cell count. JOURNAL OF CLINICAL APHERESIS , vol.37, no.1, 19-24.

KÜPELİ, SERHAN Et Al. "Total nucleated cell dose in graft is a better prognostic factor for survival in pediatric patients transplanted with bone marrow compared to CD34+, CD3+, or total mononuclear cell count," JOURNAL OF CLINICAL APHERESIS , vol.37, no.1, 19-24, 2022

KÜPELİ, SERHAN Et Al. "Total nucleated cell dose in graft is a better prognostic factor for survival in pediatric patients transplanted with bone marrow compared to CD34+, CD3+, or total mononuclear cell count." JOURNAL OF CLINICAL APHERESIS , vol.37, no.1, pp.19-24, 2022

KÜPELİ, S. Et Al. (2022) . "Total nucleated cell dose in graft is a better prognostic factor for survival in pediatric patients transplanted with bone marrow compared to CD34+, CD3+, or total mononuclear cell count." JOURNAL OF CLINICAL APHERESIS , vol.37, no.1, pp.19-24.

@article{article, author={SERHAN KÜPELİ Et Al. }, title={Total nucleated cell dose in graft is a better prognostic factor for survival in pediatric patients transplanted with bone marrow compared to CD34+, CD3+, or total mononuclear cell count}, journal={JOURNAL OF CLINICAL APHERESIS}, year=2022, pages={19-24} }